NASDAQ:TNGX Tango Therapeutics Q4 2024 Earnings Report $24.92 +0.29 (+1.18%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$25.35 +0.43 (+1.74%) As of 09/25/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tango Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.32Beat/MissMissed by -$0.03One Year Ago EPSN/ATango Therapeutics Revenue ResultsActual Revenue$4.12 millionExpected Revenue$7.84 millionBeat/MissMissed by -$3.72 millionYoY Revenue GrowthN/ATango Therapeutics Announcement DetailsQuarterQ4 2024Date2/27/2025TimeBefore Market OpensConference Call DateThursday, February 27, 2025Conference Call Time7:00AM ETUpcoming EarningsTango Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tango Therapeutics Earnings HeadlinesIl principale responsabile contabile di Tango Therapeutics vende azioni per $198kSeptember 25 at 8:40 AM | it.investing.comTango Therapeutics (NASDAQ:TNGX) Shares Up 6% - What's Next?September 24 at 5:41 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 22, 2026 | americanbankingnews.comTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comTango Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 1, 2026 | globenewswire.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX) is a biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities. The company uses genetic screening, functional genomics and drug-discovery technologies to identify cancer-specific dependencies that may be addressed with targeted therapies. Tango’s research activities center on precision oncology and immuno-oncology, including programs designed to selectively eliminate tumor cells or improve the ability of the immune system to recognize and attack cancer. Its pipeline has included small-molecule drug candidates aimed at genetically defined cancer targets, as well as programs intended to enhance immune-cell activity. Founded in 2017 and headquartered in Cambridge, Massachusetts, Tango Therapeutics originated from research associated with the Broad Institute of MIT and Harvard. The company has also pursued strategic collaborations, including a major research and development collaboration with Gilead Sciences focused on discovering and developing cancer therapies. Tango is led by President and Chief Executive Officer Barbara Weber, M.D.View Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
